Magnetic and fluorescent reverse nanoassemblies

Patent metadata

Field	Value
Publication number	US-9597418-B2
Application number	US-201414218368-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Mar 18, 2014
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

The present invention relates to magnetic and fluorescent nanoassemblies having reverse architectures. Especially, the nanoassemblies of the invention comprise a fluorescent core and magnetic nanoparticles contacting the surface of the fluorescent core. The nanoassemblies of the invention may further be coated by a polymer, which may optionally be functionalized. The invention further relates to a process for manufacturing the nanoassemblies of the invention. The invention is also directed to the use of the nanoassemblies of the invention, especially for multimodal imaging, in vitro and/or in vivo diagnostics through multimodal imaging, and/or therapy.

First claim

The invention claimed is:

1. A nanoassembly comprising:
one single fluorescent core comprising fluorescent organic molecules, and
magnetic nanoparticles contacting the surface of said fluorescent core;
wherein the fluorescent core does not comprise a polymer or silica; and
wherein the nanoassembly has a hydrodynamic diameter ranging from 20 to 800 nm.

2. The nanoassembly according to claim 1 , wherein the fluorescent organic molecules are compounds of Formula I,

wherein:
X represents O or CH 2 ;
n represents an integer selected from 1, 2, 3 and 4;
R 1 represents —CO 2 H or —P(O)(OH) 2 ;
R 2 , R 3 , R 4 , R 5 , R 6 and R 7 represent each independently an optionally functionalized group selected from alkyl and ester or polyethylene glycol, preferably R 2 , R 3 , R 4 , R 5 , R 6 and R 7 represent each a methyl group.

3. The nanoassembly according to claim 1 , wherein the magnetic nanoparticles are superparamagnetic nanoparticles selected from the group comprising γ-Fe 2 O 3 and Fe 3 O 4 .

4. The nanoassembly according to claim 1 , having a hydrodynamic diameter ranging from 20 to 700 nm.

5. The nanoassembly according to claim 1 , wherein the fluorescent core comprises a number of organic fluorescent molecule ranging from 1×10 4 to 1×10 7 .

6. The nanoassembly according to claim 1 , comprising a number of magnetic nanoparticles ranging from 1×10 2 to 1×10 6 .

7. The nanoassembly according to claim 1 , further comprising at least one polymer contacting at least one of the magnetic nanoparticle or the surface of the core.

8. The nanoassembly according to claim 7 , wherein the polymer is an ionic polymer, preferably a polyelectrolyte.

9. The nanoassembly according to claim 7 , wherein the polymer is of Formula II,

wherein,
m represents a positive integer ranging from 20 to 150;
x, y and z represent each independently a percentage of m, ranging from 0% to 100% of m, wherein x+y+z is equal to 100% of m;
X represents —COOH, alkyl, aryl; Y represents —(C═O)—O-L 1 -R 8 , —(C═O)—S-L 1 -R 8 , —(C═O)—NH(-L 1 -R 8 ) or —(C═S)—NH(-L 1 -R 8 ) wherein
L 1 represents a spacer selected from alkyl, alkene, aryl, arylalkyl, polyethylene glycol or polypropylene glycol linking groups having 1 to 150 chain atoms, wherein the linking group can be optionally interrupted or terminated by one or more —O—, —S—, —NR 9 —, —CO—, —NHCO—, —CONH— or a combination thereof, wherein R 9 is H or alkyl;
R 8 represents a reactive group selected from N 3 , amino, alkylamino, COOH, amide, maleimide, alkyne, SH, OH, ester, activated ester, activated carboxylic acid, halo, nitro, nitrile, isonitriles, acrylamide, aldehyde, ketone, acetals, ketals, anhydride, glutaric anhydride, succinic anhydride, maleic anhydride, thiocyanate, isothiocyanate, isocyanate, hydrazide, hydrazines, hydrazones, ethers, oxides, cyanates, diazo, diazonium, sulfides, disulfides, sulfoxides, sulfones, sulfonic acids, sulfinic acids, sulfates, sulfenic acids, amidines, imides, imidates, nitrones, hydroxylamines, oximes, hydroxamic acids, thiohydroxamic acids, allenes, ortho esters, sulfites, enamines, ynamines, ureas, pseudoureas, semicarbazides, carbodiimides, carbamates, imines, acetylene, olefins, polyenes, alkylacrylates, oxetane, ammoniums, oxoniums, phosphoniums, sulfoniums, positively charged metal complexes;

Z represents —(C═O)—O-L 2 -R 10 , —(C═O)—S-L 2 -R 10 , —(C═O)—NH(-L 2 -R 10 ) or —(C═S)—NH(-L 2 -R 10 ) wherein
L 2 represents a single bond or a spacer selected from alkyl, alkene, aryl, arylalkyl, polyethylene glycol or polypropylene glycol linking groups having 1 to 150 chain atoms, wherein the linking group can be optionally interrupted or terminated by one or more —O—, —S—, —NR 9 —, —CO—, —NHCO—, —CONH— or a combination thereof, wherein R 9 is H or alkyl; optionally additionally comprising a residue of a reactive group through which L 2 is bonded to R 10 ;
R 10 represents a bioactive group selected from amino acid, peptide, protein, antibody, enzyme, polysaccharide, dextran, benzylguanine, lipid, lipid assembly, fatty acid, nucleoside, nucleotide, oligonucleotide, hapten, aptamer, ligand, substrate, biotin, avidin, synthetic polymer, polyethylene glycol, polypropylene glycol, polymeric microparticle, nanoparticle, fluorophore, chromophore, radioisotope, macrocyclic complexes of radioisotope, and combinations thereof.

10. The nanoassembly according to claim 7 , wherein the polymer is polyacrylic acid.

11. The nanoassembly according to claim 7 , having a hydrodynamic diameter ranging from 50 to 800 nm.

12. A pharmaceutical composition comprising the nanoassembly according to claim 1 , in combination with at least one pharmaceutically acceptable vehicle.

13. A medicament comprising the nanoassembly according to according to claim 1 .

14. A pharmaceutical composition comprising the nanoassembly according to claim 7 , in combination with at least one pharmaceutically acceptable vehicle.

15. A medicament comprising the nanoassembly according to according to claim 7 .

Assignees

• Univ Nantes
• Centre Nat De La Rech Scient (Cnrs)

Inventors

• Ishow Elena
• Faucon Adrien

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K41/0042

  Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion · CPC title

• A61K49/10

  Organic compounds · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title